LUNG CANCER

Considerations for Treating Locally Advanced NSCLC

Consolidation Therapy for Locally Advanced NSCLC

A supplemental biologics license application has been accepted by the FDA seeking approval for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden  ≥10 mutations per megabase, according to Bristol-Myers Squibb, the manufacturer of both immune checkpoint inhibitors.

The Hutchinson Institute for Cancer Outcomes Research released the first Community Care Cancer in Washington State: Quality and Cost Report to provide transparency for patients and health providers, establishing a more value-based care model.

Osimertinib (Tagrisso) has been approved by The European Commission as a frontline treatment for patients with&nbsp;<em>EGFR</em>-mutant locally-advanced or metastatic non&ndash;small cell lung cancer. The approval is based on data&nbsp;from the phase III FLAURA trial.

Robert L. Ferris, MD, PhD, Physician Editor-In-Chief of the Journal of Targeted Therapies, discusses&nbsp;genomic rearrangements and the allelic fraction of that genomic rearrangement as a major component of an individual&rsquo;s cancer.